Abstracts Archive - Page 1657 of 2607 - ACR Meeting Abstracts

Abstract Number: 863 • 2016 ACR/ARHP Annual Meeting
Arterial Lesions in Giant Cell Arteritis
Tanaz A. Kermani¹, Sehriban Diab², Antoine Sreih³, David Cuthbertson⁴, Renee Borchin⁵, Simon Carette⁶, Lindsy J. Forbess⁷, Gary S. Hoffman⁸, Curry L. Koening⁹, Carol A. McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Christian Pagnoux¹³, Philip Seo¹⁴, Robert F. Spiera¹⁵, Kenneth J. Warrington¹⁶, Steven R. Ytterberg¹⁷, Carol A. Langford¹⁸, Nader A. Khalidi¹⁹ and Peter A. Merkel²⁰, ¹Rheumatology, University of California Los Angeles, Santa Monica, CA, ²St. Joseph’s Healthcare, McMaster University, Hamilton, ON, Canada, ³Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵University of South Florida, Tampa, FL, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ⁹Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology, Boston University School of Medicine, Boston, MA, ¹²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ¹⁴Medicine, Johns Hopkins University, Baltimore, MD, ¹⁵Hospital for Special Surgery, Cornell, New York, NY, ¹⁶Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ¹⁷Rheumatology, Mayo Clinic, Rochester, MN, ¹⁸Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁹Division of Rheumatology, St. Joseph’s Health Care, McMaster University, Hamilton, ON, Canada, ²⁰Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: This study aimed to describe large arterial lesions among patients with giant cell arteritis (GCA) and to understand what clinical characteristics are associated…
Abstract Number: 864 • 2016 ACR/ARHP Annual Meeting
Takayasu Arteritis Developed over the Age of 40 Has Lower Levels of Interferon Gamma and Interleukin 17 at Disease Onset and Fewer Subsequent Relapses
Shoichi Fukui¹, Naoki Iwamoto², Toshimasa Shimizu², Masataka Umeda², Ayako Nishino³, Yoshiro Horai², Tomohiro Koga⁴, Shin-ya Kawashiri⁵, Kunihiro Ichinose¹, Yasuko Hirai², Mami Tamai¹, Hideki Nakamura⁵, Tomoki Origuchi⁶, Kiyoshi Migita⁷, Yukitaka Ueki⁸ and Atsushi Kawakami⁹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki Universit, Nagasaki, Japan, ⁴Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁷Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ⁸Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, ⁹Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis (TAK) include age at disease onset ≤ 40 years. We aimed…
Abstract Number: 865 • 2016 ACR/ARHP Annual Meeting
Poor Predictive Value of Isolated Adventitial and Periadventitial Infiltrates in Temporal Artery Biopsies for Diagnosis of Giant Cell Arteritis
Claire Le Pendu¹, Véronique Meignin², Solange Gonzalez-Chiappe³, Françoise Galateau-Sallé⁴ and Alfred Mahr³, ¹Internal Medicine, Hospital Saint Louis, PARIS, France, ²Pathology, Saint Louis Hospital, PARIS, France, ³Internal Medicine, Hospital Saint-Louis, Paris, France, ⁴Pathology, Caen Hospital, Caen, France
Background/Purpose: Histological findings of intima-media or transmural inflammation in temporal artery biopsies (TABs) have undisputed high value for diagnosis of giant cell arteritis (GCA). Conversely,…
Abstract Number: 866 • 2016 ACR/ARHP Annual Meeting
Perivascular Inflammation in Temporal Artery Biopsies That Are Negative for Arteritis: Incidental or Harbinger?
Yousef Zarbalian¹, Kimberly P. Liang², Ronald L. Hamilton³, Li Wang⁴ and Dan Winger⁵, ¹Medicine, Division of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Pathology, Division of Neuropathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Office of Clinical Research, University of Pittsburgh, Pittsburgh, PA, ⁵Office of Clinical Research, Health Sciences, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The diagnosis of giant cell arteritis (GCA) by temporal artery (TA) biopsy requires pathologic identification of arterial inflammation, usually with giant cells. However, some…
Abstract Number: 867 • 2016 ACR/ARHP Annual Meeting
Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137)
Sabine Adler¹, Stephan Reichenbach², Stefan Kuchen³, Felix Wermelinger⁴, Diana Dan⁴, Michael Seitz⁴ and Peter M. Villiger⁴, ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland, ⁴Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose:
Abstract Number: 868 • 2016 ACR/ARHP Annual Meeting
Infections and the Risk of Incident Giant Cell Arteritis: A Population-Based, Case-Control Study
Rennie L. Rhee¹, Peter C. Grayson², Peter A. Merkel³ and Gunnar Tomasson⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ⁴Dept of Public Health Sciences, University of Iceland, Reykjavik, IS
Background/Purpose : Alterations in the immune system and infections are suspected to increase susceptibility to giant cell arteritis (GCA). Recently herpes zoster has been…
Abstract Number: 869 • 2016 ACR/ARHP Annual Meeting
Low Numbers of CD16+ Monocytes Predict Shorter Time to Relapse in Polymyalgia Rheumatica
Qi Wang¹, Kornelis S.M. van der Geest², Wayel H. Abdulahad¹, Abraham Rutgers¹, Suzanne Arends¹, Annemieke M.H. Boots¹ and Elisabeth Brouwer³, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) is the most frequent inflammatory disorder in persons older than 50 years of age. Biomarkers like ESR and CRP may be…
Abstract Number: 870 • 2016 ACR/ARHP Annual Meeting
Contemporary Prevalence Estimates for Giant Cell Arteritis and Polymyalgia Rheumatica, 2015
Cynthia S. Crowson¹ and Eric L. Matteson², ¹Health Sciences Research, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: There are no estimates of the prevalence of giant cell arteritis (GCA) or polymyalgia rheumatic (PMR) in a United States population in the current…
Abstract Number: 871 • 2016 ACR/ARHP Annual Meeting
Interleukin 33 Critically Regulates Angiogenesis and Inflammation in Large Vessels Vasculitis
Anne-Claire Desbois¹, Aurélie LEROYER², Marlène Garrido³, Julien Gaudric⁴, Cloé Comarmond⁵, David Klatzman⁶, Philippe Cluzel⁷, Pierre Fouret⁸, Laurent Chiche⁹, Fabien Koskas¹⁰, Gilles Kaplanski¹¹, Patrice Cacoub¹² and David Saadoun¹³, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²Faculté de Pharmacie, Marseille, France, ³I3 laboratory, Pitié-Salpétrière, Paris, France, ⁴Department of Vascular surgery GHPS, Paris, France, ⁵DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁶UPMC Université Paris 06, UMR 7211, Paris, France, ⁷Cadiovascular Imaging and Interventional Radiology, Pitié-Salpétrière, Paris, France, ⁸Hôpital La Pitié Salpétrière, Paris, France, ⁹Service de Chirurgie Vasculaire, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ¹⁰Department of Internal Medicine and 2Laboratory I3 « Immunology, Immunopathology, Immunotherapy », UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ¹¹Aix-Marseille Université - Internal Medicine hopital conception - F-13000 Marseilles, Marseille, France, ¹²Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ¹³Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France
Background/Purpose: Large vessels vasculitis (LVV) include Takayasu disease (TD) and Giant Cell Arteritis (GCA). Interleukin 33 (IL-33) is a cytokine which controls immune responses and…
Abstract Number: 872 • 2016 ACR/ARHP Annual Meeting
New Insights into the Pathogenesis of Giant Cell Arteritis through a Genome-Wide Association Study
Francisco David Carmona¹, Augusto Vaglio², Sarah Mackie³, José Hernández-Rodríguez⁴, Paul A. Monach⁵, Santos Castañeda⁶, Roser Solans⁷, Inmaculada C. Morado⁸, Francisco Javier Narváez⁹, Marc Ramentol-Sintas¹⁰, Colin T. Pease¹¹, Bhaskar Dasgupta¹², Richard Watts¹³, Nader A. Khalidi¹⁴, Carol A. Langford¹⁵, Steven R. Ytterberg¹⁶, Luigi Boiardi¹⁷, Lorenzo Beretta¹⁸, Marcello Govoni¹⁹, Giacomo Emmi²⁰, Francesco Bonatti²¹, Marco A. Cimmino²², Torsten Witte²³, Thomas Neumann²⁴, Julia Holle²⁵, Verena Schönau²⁶, Laurent Sailler²⁷, Thomas Papo²⁸, Julien Haroche²⁹, Alfred Mahr³⁰, Luc Mouthon³¹, Øyvind Molberg³², Andreas P Diamantopoulos³³, Alexandre E. Voskuyl³⁴, Elisabeth Brouwer³⁵, Thomas Daikeler³⁶, Christoph Berger³⁷, Eamonn S. Molloy³⁸, Lorraine O'Neill³⁹, Daniel Blockmans⁴⁰, Benedicte A. Lie⁴¹, Paul Mclaren⁴², Timothy J. Vyse⁴³, Cisca Wijmenga⁴⁴, Yannick Allanore⁴⁵, Bobby P.C. Koeleman⁴⁶, Jennifer H. Barrett⁴⁷, Maria C. Cid⁴⁸, Carlo Salvarani⁴⁹, Peter A. Merkel⁵⁰, Ann W. Morgan⁵¹, Miguel Angel González-Gay⁵², Javier Martín¹ and Spanish GCA Group, UKGCA Consortium, and Vasculitis Clinical Research Consortium, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ²Nephrology, University Hospital of Parma, Parma, Italy, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, ⁴Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ⁷Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ⁸Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁹Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, ¹⁰Internal Medicine, Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain, ¹¹Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹²Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ¹³Rheumatology, Ipswich Hospital NHS Trust, Ipswich, United Kingdom, ¹⁴Rheumatology, McMaster University, Hamilton, ON, Canada, ¹⁵Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁶Rheumatology, Mayo Clinic, Rochester, MN, ¹⁷Rheumatology Unit, Department of Internal Medicine, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ¹⁸Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁹Medical Sciences, UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ²⁰Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²¹Clinical and Experimental Medicine, Medical Genetics Unit, University of Parma, Parma, Italy, ²²Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²³Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ²⁴Internal Medicine III, Jena University Hospital, Jena, Germany, ²⁵Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ²⁶Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany, ²⁷Internal Medicine, Internal Medicine department, Toulouse University Hospital, Toulouse, France, ²⁸Internal Medicine, Hôpital Bichat, Université Paris-Diderot, Paris, France, ²⁹Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ³⁰Internal Medicine, Hospital Saint-Louis, Paris, France, ³¹Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ³²Rheumatology, Oslo University Hospital, Oslo, Norway, ³³Rheumatology, Haugesund Sanitetsforenings Revmatismesykehus, Haugesund, Norway, ³⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, ³⁵Rheumatology and Clinical Immunology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands, ³⁶Rheumatology, University Hospital Basel, Basel, Switzerland, ³⁷Internal medicine, University hospital Basel, basel, Switzerland, ³⁸Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland, ³⁹Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴⁰General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁴¹Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway, ⁴²Swiss Institute of Bioinformatics, Lausanne, Switzerland, ⁴³Division of Immunology, Infection and Inflammatory Disease, King’s College London, London, United Kingdom, ⁴⁴Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, ⁴⁵Rheumatology, Paris Descartes University, Paris, France, ⁴⁶Medical Genetics, University Medical Centre Utrecht, Utrecht, Netherlands, ⁴⁷NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴⁸Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁴⁹Rheumatology, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ⁵⁰Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵¹Section of Musculoskeletal Disease, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁵²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is an immune-mediated polygenic disease characterized by inflammatory lesions in medium- and large-sized arteries. The aim of the present study…
Abstract Number: 873 • 2016 ACR/ARHP Annual Meeting
Interleukin-23 Stimulates Inflammatory and Proliferative Pathways in Giant Cell Arteritis
Richard Conway¹, Karen Creevey², Michelle Trenkmann³, Geraldine M. McCarthy⁴, Conor Murphy⁵, Douglas J. Veale⁶, Ursula Fearon⁷ and Eamonn S. Molloy⁸, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²St. Vincent's University Hospital, Centre for Athritis and Rheuamtic Diseases, Dublin Academic Medical Centre,, Dublin, Ireland, ³St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ⁴Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁵Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁶Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ⁷Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁸Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis. The pathogenesis of GCA remains incompletely understood. Current evidence suggests that dendritic…
Abstract Number: 874 • 2016 ACR/ARHP Annual Meeting
Expression and Function of IL-12/23 Related Cytokine Subunits (p35, p40 and p19) in Giant-Cell Arteritis Lesions. Potential Role of p40 in Promoting Th1 -Mediated Pathways
Georgina Espígol-Frigolé¹, Ester Planas-Rigol¹, Ester Lozano², Marc Corbera-Bellalta², Nekane Terrades-Garcia², Sergio Prieto-González¹, Ana García-Martínez³, Jose Hernández-Rodríguez² and Maria C. Cid⁴, ¹Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Emergeny Department, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁴Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: GCA has been considered a Th1-mediated disease. In recent years it has become apparent that Th17-mediated mechanisms may also play a role in GCA…
Abstract Number: 875 • 2016 ACR/ARHP Annual Meeting
Pericardial Involvement in Biopsy-Proven Giant-Cell Arteritis (GCA) Patients Detected By CT Angiography (CTA): Prevalence at Diagnosis and Outcome with Glucocorticoid (GC) Treatment
Javier Marco-Hernández¹, Sergio Prieto-González², Rosa Gilabert³, Pedro Arguis⁴, Georgina Espígol-Frigolé⁵, Ana García-Martínez⁶, Ester Planas-Rigol⁵, Marc Corbera-Bellalta², Nekane Terrades-Garcia², Jose Hernández-Rodríguez² and Maria C. Cid⁷, ¹Internal Medicine, Hospital Clínic, Barcelona, Spain, ²Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Center for Diagnostic Imaging, Hospital Clínic, Barcelona, Spain, ⁴Center for Diagnostic Imaging, Hospital Clínic. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁵Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁶Emergeny Department, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁷Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: In GCA, cranial artery involvement is particularly frequent and underlies the classical manifestations and complications of the disease. Symptomatic pericarditis has been occasionally described…
Abstract Number: 876 • 2016 ACR/ARHP Annual Meeting
Long Term Efficacy of Ustekinumab for the Treatment of Giant Cell Arteritis
Richard Conway¹, Lorraine O'Neill², Phil Gallagher³, Eileen O'Flynn⁴, Geraldine M. McCarthy⁵, Conor Murphy⁶, Douglas J. Veale⁷, Ursula Fearon⁸ and Eamonn S. Molloy⁹, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁴Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁵Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁶Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁷Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ⁸Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁹Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high dose corticosteroids with attendant significant adverse events. There is a critical need for alternative therapies. Interleukins…
Abstract Number: 877 • 2016 ACR/ARHP Annual Meeting
Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Matthew J. Koster², Kenneth J. Warrington³ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN
Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-analysis Background/Purpose: Several chronic inflammatory disorders, such as rheumatoid arthritis and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].